Loading...
XSTO
MCAP
Market cap681mUSD
May 30, Last price  
435.50SEK
1D
-0.69%
1Q
12.87%
Jan 2017
1,150.72%
IPO
3,238.46%
Name

MedCap AB (publ)

Chart & Performance

D1W1MN
P/E
31.46
P/S
3.61
EPS
13.84
Div Yield, %
—
Shrs. gr., 5y
2.08%
Rev. gr., 5y
19.00%
Revenues
1.81b
+13.82%
188,857,000187,055,000258,787,000315,887,000336,510,000349,041,000826,086,000852,754,000816,918,000851,668,000411,200,000709,000,000757,100,000817,400,000916,300,0001,111,400,0001,587,400,0001,806,800,000
Net income
207m
+20.44%
-7,727,000114,0005,797,00013,511,00010,705,00017,112,00022,608,0008,524,00019,452,00073,0002,100,000600,00053,700,00060,900,00096,500,000117,600,000172,200,000207,400,000
CFO
360m
+57.89%
2,146,0003,373,00017,317,00030,637,00028,749,00038,550,000865,0002,258,000-14,917,00081,456,00027,300,00090,600,00071,400,000115,600,000116,300,00085,500,000228,000,000360,000,000
Earnings
Jul 23, 2025

Profile

MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, growth capital, middle market, mature, turnarounds, buyout. It prefers to invest in healthcare equipment and services, biotechnology, life sciences, and pharmaceuticals companies. The firm prefers to invest in small to medium size companies that are not listed on the stock exchange and are based in Northern Europe. It typically invests between SEK25 million ($2.75 million) to SEK150 million ($16.51 million) with enterprise value and sales revenue between SEK50 million ($5.90 million) to SEK200 million ($23.06 million) and EBITDA between SEK1 million ($0.11 million) to SEK50 million ($5.50 million). The firm seeks to acquire stakes between 20% and 50% in its portfolio companies. It uses its capital and loans and makes balance sheet investments. MedCap AB (publ) was founded in 2001 and is based in Stockholm, Sweden.
URL
https://www.medcap.se/
IPO date
Jul 04, 2006
Employees
463
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122017‑042016‑04
Income
Revenues
1,806,800
13.82%
1,587,400
42.83%
1,111,400
21.29%
Cost of revenue
749,600
675,500
683,000
Unusual Expense (Income)
NOPBT
1,057,200
911,900
428,400
NOPBT Margin
58.51%
57.45%
38.55%
Operating Taxes
52,300
49,800
34,000
Tax Rate
4.95%
5.46%
7.94%
NOPAT
1,004,900
862,100
394,400
Net income
207,400
20.44%
172,200
46.43%
117,600
21.87%
Dividends
Dividend yield
Proceeds from repurchase of equity
35,900
1,800
(9,100)
BB yield
Debt
Debt current
60,600
69,000
116,100
Long-term debt
581,400
339,400
379,700
Deferred revenue
Other long-term liabilities
12,300
33,200
5,700
Net debt
271,900
219,800
259,400
Cash flow
Cash from operating activities
360,000
228,000
85,500
CAPEX
(41,700)
(22,100)
(44,300)
Cash from investing activities
(128,800)
(152,300)
(56,100)
Cash from financing activities
(46,100)
(119,700)
61,200
FCF
877,100
819,000
275,000
Balance
Cash
370,100
188,200
236,200
Long term investments
400
200
Excess cash
279,760
109,230
180,830
Stockholders' equity
6,200
598,800
430,400
Invested Capital
1,652,300
1,212,270
998,770
ROIC
70.16%
77.98%
42.15%
ROCE
61.44%
65.69%
35.16%
EV
Common stock shares outstanding
14,910
14,857
14,807
Price
Market cap
EV
EBITDA
1,172,600
1,015,900
516,200
EV/EBITDA
Interest
19,000
15,600
16,400
Interest/NOPBT
1.80%
1.71%
3.83%